Top Picks From ADA
Top Picks From ADA
Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you from the annual American Diabetes Association meeting in Chicago, Illinois. I would like to summarize the abstracts that I have found interesting — not everything of note, but the abstracts that I believe are clinically the most important.
A few of these are new developments, the first of which is the artificial pancreas. Everyone likes the idea of the artificial pancreas, even if the reality is still years away. I will also discuss some of the new drugs and combination drugs that incorporate different types of long-acting insulin, different types of glucagon-like peptide 1 (GLP-1) receptor agonists, and the newest class of drugs, the sodium glucose co-transporter 2 (SGLT2) inhibitors. Those are the areas which have seen the most movement in the field in terms of new data and new ideas for treating our patients.
Clinical Developments in Diabetes
Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you from the annual American Diabetes Association meeting in Chicago, Illinois. I would like to summarize the abstracts that I have found interesting — not everything of note, but the abstracts that I believe are clinically the most important.
A few of these are new developments, the first of which is the artificial pancreas. Everyone likes the idea of the artificial pancreas, even if the reality is still years away. I will also discuss some of the new drugs and combination drugs that incorporate different types of long-acting insulin, different types of glucagon-like peptide 1 (GLP-1) receptor agonists, and the newest class of drugs, the sodium glucose co-transporter 2 (SGLT2) inhibitors. Those are the areas which have seen the most movement in the field in terms of new data and new ideas for treating our patients.
Source...